Anonymous
Guest
Anonymous
Guest
It seems that consultants run all of the pharma companies. Perhaps there is an alternative solution when product approval productivity is low.
Maybe freezes or reductions in expenses would negate the need for drastic termination measures. I believe, if analysis confirms, that the following would be options:
Salary reduction across the board (including top execs) (say 10%).
Temporary elimination of bonuses
Major caps on expenses (eliminate lunch programs)
Eliminate consultant contracts. If leaders cannot lead, get rid of them.
Make minor adjustments to benefits
These temporary measures may produce the same savings to the company. As new innovations are approved, increases in pay and benefits would be implemented. Those who want to leave can leave.
Maybe freezes or reductions in expenses would negate the need for drastic termination measures. I believe, if analysis confirms, that the following would be options:
Salary reduction across the board (including top execs) (say 10%).
Temporary elimination of bonuses
Major caps on expenses (eliminate lunch programs)
Eliminate consultant contracts. If leaders cannot lead, get rid of them.
Make minor adjustments to benefits
These temporary measures may produce the same savings to the company. As new innovations are approved, increases in pay and benefits would be implemented. Those who want to leave can leave.